Pacira BioSciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:00 PM ET. Interested parties can access the live audio via the company's website, with a replay available for two weeks post-event. Pacira is dedicated to providing non-opioid pain management solutions and has three commercial-stage products: EXPAREL®, ZILRETTA®, and ioveraº®. Their mission focuses on reducing reliance on opioids and developing innovative treatments for chronic pain and related conditions.
Positive
- None.
Negative
- None.
News Market Reaction – PCRX
In the trading session that priced this news, PCRX gained 1.71%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, Fla., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference at 3:00 PM ET on Monday, January 10, 2022. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
